Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Connors Investor Services Inc.

Connors Investor Services Inc. reduced its stake in Omnicell, Inc. (NASDAQ:OMCL) by 15.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 75,542 shares of the company’s stock after selling 13,507 shares during the period. Connors Investor Services Inc. owned 0.16% of Omnicell worth $3,363,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of OMCL. Schonfeld Strategic Advisors LLC boosted its position in shares of Omnicell by 277.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 21,770 shares of the company’s stock valued at $969,000 after purchasing an additional 16,003 shares during the period. Northern Trust Corp raised its holdings in shares of Omnicell by 14.1% in the fourth quarter. Northern Trust Corp now owns 565,026 shares of the company’s stock valued at $25,155,000 after buying an additional 69,916 shares during the last quarter. Aquatic Capital Management LLC boosted its stake in shares of Omnicell by 24.7% during the fourth quarter. Aquatic Capital Management LLC now owns 26,061 shares of the company’s stock worth $1,160,000 after buying an additional 5,161 shares during the period. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell in the 4th quarter worth $37,000. Finally, Oberweis Asset Management Inc. acquired a new position in Omnicell during the 4th quarter worth approximately $14,834,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

OMCL has been the subject of several research reports. Wells Fargo & Company cut their price target on Omnicell from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a report on Friday, April 25th. Bank of America decreased their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. JPMorgan Chase & Co. dropped their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 20th. Finally, Benchmark reiterated a “buy” rating and issued a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $50.67.

Omnicell Stock Up 1.8 %

Shares of NASDAQ:OMCL opened at $31.40 on Wednesday. The company has a fifty day simple moving average of $33.97 and a 200 day simple moving average of $40.70. The firm has a market cap of $1.47 billion, a PE ratio of 116.30, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.